BLTE

BELITE BIO, INC BLTE

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-77.61M

Quarter to Dec 31

Free cash flow

$-37.06M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$1.44B total
Darwin Global Management, Ltd.
$456.59M+0.6%
Paradigm Biocapital Advisors LP
$189.84M+10.6%
RTW INVESTMENTS, LP
$110.15M0.0%
MILLENNIUM MANAGEMENT LLC
$76.16M-13.2%
MAVERICK CAPITAL LTD
$61.03MNew
EVENTIDE ASSET MANAGEMENT, LLC
$60.18M+9.3%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$55.00M+17.5%
Holocene Advisors, LP
$38.66M-49.2%
Logos Global Management LP
$38.50MNew
MORGAN STANLEY
$36.20M+16.7%
UBS Group AG
$34.64M-70.7%
CITADEL ADVISORS LLC
$28.67M+9171.3%
GOLDMAN SACHS GROUP INC
$25.59M+57.5%
Affinity Asset Advisors, LLC
$25.41M+153.8%
MPM BioImpact LLC
$21.13M+55.8%
BANK OF AMERICA CORP /DE/
$19.21M+3202.9%
Patient Square Capital LP
$16.94M-5.7%
Duquesne Family Office LLC
$16.34M0.0%
PRICE T ROWE ASSOCIATES INC /MD/
$16.30M-62.4%
JANE STREET GROUP, LLC
$10.13M+438.4%
BNP PARIBAS FINANCIAL MARKETS
$8.80M+75.6%
RENAISSANCE TECHNOLOGIES LLC
$8.59M+7.2%
Point72 Asset Management, L.P.
$7.88MNew
Soleus Capital Management, L.P.
$7.78MNew
Trexquant Investment LP
$7.62M+228.5%
See all 81 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

BLTE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About BELITE BIO, INC (BLTE): stock profile, AI score and financials

BELITE BIO, INC (BLTE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BLTE is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (FY 2025), BELITE BIO, INC reports net income of $-77.6M, free cash flow of $-37.1M. Top institutional holders of BLTE by reported 13-F value include Darwin Global Management, Ltd., Paradigm Biocapital Advisors, RTW INVESTMENTS, based on the most recent SEC filings. BLTE trades on the Nasdaq exchange and files with the SEC under CIK 1889109. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLTE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BELITE BIO, INC directly from SEC EDGAR.

SEC EDGAR: CIK 1889109 →